Status:
WITHDRAWN
Precision Medicine Approach to Unravel the Risk Factors for Renal, Cardiovascular, Ophthalmologic, Neurologic and Hepatic Complications of Metabolic Disorders
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsors:
Centre Hospitalier Universitaire, Amiens
Biobanque de Picardie
Conditions:
Chronic Kidney Diseases
Diabetes
Eligibility:
All Genders
18-65 years
Brief Summary
There is currently no way to predict the progression of chronic kidney disease in patients with metabolic disease(s). Furthermore, the mechanisms responsible for the development and/or progression of ...
Detailed Description
Eligible patients will be detected during one of their consultations at the precision medicine center of the Amiens-Picardy University Hospital. They will be informed of the proposed research pathway ...
Eligibility Criteria
Inclusion
- Adult persons, male or female, age ≥ 18 and ≤ 65 years
- Persons able to understand the information provided and to object to it (at the discretion of the investigator)
- Patient affiliated to a social security system.
- Patient willing to sign an informed consent form
- Patient with the following metabolic profile Diabetic (of any type) treated or not (diabetes will be defined by a fasting blood glucose \> 7mM or a HbA1c \> 6.5% or by the use of an antidiabetic treatment) AND/OR Obese patient (BMI \> 30 kg/m2) treated or not
- Patient with evidence of renal parenchymal damage defined by an albuminuria/creatinuria ratio ≥ 3 mg/mmol (30mg/g), AND/OR a glomerular filtration rate estimated by the CKD-EPI (eDFG) formula classifying the patient as stage 2 to 3a of the KDIGO classification (i.e., 90ml/min/1.73 m2 \> GFR \> 45ml/min), AND/OR a renal lithiasis
Exclusion
- Patient deprived of liberty
- Person subject to a legal protection measure (guardianship, curatorship or safeguard of justice)
- Patient refusing to participate in the study
- Pregnant, parturient or nursing woman
- Patient in emergency situation
- Patient with advanced chronic kidney disease defined as GFR \< 45ml/min/1.73 m².
- Contraindication to Iohexol injection
- Patient with or who has had any of the following complications: symptomatic coronary artery disease, symptomatic peripheral arterial disease, previous stroke, previous myocardial infarction, heart failure ≥ stage B, dementia, liver fibrosis, hepatocarcinoma.
Key Trial Info
Start Date :
May 3 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 3 2032
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05307172
Start Date
May 3 2022
End Date
May 3 2032
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire d'AMIENS - Picardie
Amiens, France, 80054